How PolyModels Hub is Building Practical, Robust, and Science-Driven Digital Solutions for Pharma

PolyModels Hub, optimizing pharma process in one place, led by Antonio Benedetti, Harry Christodoulou, PhD, and Antonio Yankey, has secured £7 million in a Series A round led by Molten Ventures, with participation from Marathon Venture Capital, to accelerate the digital transformation of biopharma process development.

The technology to truly automate AR didn’t exist until recently. Stuut now executes AR end-to-end, from outreach to payment collection, using AI that maintains full context across every customer interaction and improves with each workflow. The platform deploys in days, not months, and begins collecting cash immediately, eliminating the long, complex implementations of traditional systems.

Developing a new drug costs about $2.5 billion, with nearly $650 million spent on process development, a massive opportunity to improve speed and efficiency. ModelFlow unifies advanced modeling, simulation, and workflow management in one digital environment, enabling scientists and engineers to design, test, and refine manufacturing processes far faster. By combining physics-based and AI-driven models with structured, traceable workflows, it reduces experimental burden, deepens process understanding, and supports confident decision-making earlier in development.

Traditional process development can require hundreds of experiments and months of work. ModelFlow cuts that workload by more than 90%, reducing 100 experiments to fewer than ten while preserving scientific rigor. As manufacturing grows more complex across molecules and modalities, teams are recognizing process development as a strategic lever, and the need for scalable, data-driven infrastructure is only accelerating.

The expansion into complex biologics and AI-driven automation advances a unified digital layer that spans discovery through commercial manufacturing with full consistency and scientific rigor. The team brings deep scientific and engineering expertise from across life sciences and technology, shaped by years of building systems in highly complex, regulated environments.

As development timelines tighten and modalities grow more complex, PolyModels Hub is giving biopharma teams the clarity and speed they need.

“Our technology has delivered measurable impact across global programs in just 18 months,” said Antonio Benedetti, CEO & co-founder. “We’re accelerating work in complex biologics and expanding our platform to give scientists the model-based tools needed to turn molecules into medicines.”

Investors noted the same momentum. Molten Ventures highlighted the team’s ability to deliver value in weeks, not years, while Marathon Venture Capital emphasized how the platform replaces outdated lab processes with data-driven, automated workflows. By unifying models, experiments, and decisions in a single environment, PolyModels Hub helps teams cut through complexity and advance better medicines to patients faster.